Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement.
Pan Y, Xue Q, Yang Y, Shi T, Wang H, Song X, Luo Y, Liu W, Ren S, Cai Y, Nie Y, Song Z, Liu B, Li JP, Wei J.
Pan Y, et al. Among authors: song z.
Cell Rep Med. 2024 May 29:101590. doi: 10.1016/j.xcrm.2024.101590. Online ahead of print.
Cell Rep Med. 2024.
PMID: 38843844
Free article.